688410.CG▲
Shanwaishan Releases 2026 Interim Report with Net Profit of 94.37 Million Yuan
Shanwaishan released its 2026 interim report on August 28, 2026. During the reporting period, the company achieved total operating revenue of 464 million yuan and net profit attributable to the parent of 94.37 million yuan. Net cash inflow from operating activities was 41.0014 million yuan, down 40.10% from the same period last year. The company's asset-liability ratio was 26.01%, gross margin was 54.67%, return on equity was 5.21%, and diluted earnings per share was 0.30 yuan. In addition, the company had 10,600 shareholders, and the top ten shareholders held a combined 53.43% of total share capital.
688410.CG▲
Shanwaishan's first-half net profit attributable to parent reaches 94.37 million yuan, up 71.5% year-on-year
Shanwaishan released its 2026 half-year report, with first-half net profit attributable to the parent of 94.37 million yuan, up 71.5% year-on-year. Operating revenue was 464 million yuan, up 29.8% year-on-year; net profit attributable to the parent after deducting non-recurring items was 84.98 million yuan, up 67.6% year-on-year; net operating cash flow was 41 million yuan, down 40.1% year-on-year; earnings per share were 0.2968 yuan. In the second quarter, operating revenue was 234 million yuan, up 39.4% year-on-year; net profit attributable to the parent was 39.89 million yuan, up 121.2% year-on-year. As of the end of the second quarter, total assets were 2.448 billion yuan, up 4.3% from the end of the previous year; net assets attributable to the parent were 1.811 billion yuan, up 1.8% from the end of the previous year. During the reporting period, sales revenue from the company's self-produced blood purification consumables rose significantly, driving overall revenue growth. Research and development investment reached 41.03 million yuan, accounting for 8.85% of operating revenue.
688410.CG▲
SWS to pay 2 yuan per 10 shares, payout ratio 94.83%
SWS announced on August 27 that it plans to distribute a cash dividend of 2 yuan, tax included, for every 10 shares to all shareholders, with total payout expected to be 89.49 million yuan, accounting for 94.83% of net profit attributable to the parent company in the first half of 2026. In the interim period of 2026, SWS achieved revenue of 464 million yuan and net profit attributable to the parent company of 94.37 million yuan.
688410.CG▲
SWS First-Half Net Profit Up 71.46% Year on Year; Proposes 2 Yuan Cash Dividend per 10 Shares
SWS disclosed its semi-annual report on August 27. In the first half of 2026, the company achieved operating revenue of 464 million yuan, up 29.8 percent year on year. Net profit attributable to shareholders of the listed company was 94.37 million yuan, up 71.46 percent year on year. Basic earnings per share were 0.2968 yuan. The company plans to distribute a cash dividend of 2 yuan, tax included, for every 10 shares. During the reporting period, the company's product market share continued to rise, driving steady growth in sales revenue from blood purification equipment. Sales revenue from self-produced blood purification consumables increased significantly. As production and sales volumes rose, the fixed cost per unit of self-produced consumables declined and gross margin improved, further strengthening overall profitability.
688410.CG▲
SWS Subsidiary Obtains Change Registration Filing for Continuous Blood Purification Tubing
Chongqing Tianwaitian Biotechnology, a wholly owned subsidiary of SWS, recently received the change registration filing document for the continuous blood purification tubing medical device from the National Medical Products Administration. The product registration certificate is valid from December 30, 2022 to December 29, 2027. In the first quarter of 2026, SWS achieved revenue of 230 million yuan and net profit attributable to the parent company of 54.48 million yuan.
Shanwaishan's major shareholder plans to cut stake by up to 4.03%, worth about 200 million yuan
Shanwaishan disclosed that major shareholder Hunan Xiangjiang Big Health Venture Capital Partnership plans to reduce its holding by no more than 18.0319 million shares through block trading, representing 4.03% of the company's total share capital. Based on the latest closing price of 11.11 yuan, the stake is worth about 200 million yuan. The reduction window runs from September 3 to December 2, 2026, with the sale price determined by market prices at the time of execution. This is the shareholder's third reduction plan in the past year, after two previous reductions totaling about 3.3675 million shares. The announcement shows that Big Health and its concert parties together hold about 40.2697 million shares, or 9.00% of total share capital, and this reduction will not lead to a change in company control. Shanwaishan's share price has risen first and fallen later this year, hitting an intra-year high of 18.47 yuan, while the latest closing price is down more than 20% from the start of the year.
SWS Subsidiary Obtains Medical Device Registration Certificate for Single-Use Hemodialysis Blood Tubing Set
SWS wholly-owned subsidiary Chongqing Tianwaitian Biotechnology Co., Ltd. has obtained a medical device registration certificate from the National Medical Products Administration for a single-use hemodialysis blood tubing set. The certificate is valid from July 20, 2026 to July 19, 2031. The product is used to establish an extracorporeal circulation pathway during hemodialysis, hemofiltration, hemodiafiltration, and hemodialysis combined with hemoperfusion treatments. In the first quarter of 2026, SWS achieved revenue of 230 million yuan and a net profit attributable to the parent company of 54.48 million yuan.
China